What Network pharmacology and target-mechanism analysis is designed to address
Network pharmacology and target-mechanism analysis is not a one-score software run. It is a reviewable analysis path organised around “Through which targets and pathways might candidate compounds create synergistic or risk mechanisms?”, beginning with input quality, comparators and intended use of evidence before selecting an appropriate methodological level.
The work centres on Target prediction and evidence grading, Disease genes, PPI and pathway networks, Topology, enrichment and mechanism-module analysis and links Compound structures or ingredient list, Disease, phenotype and tissue context, Optional experimental targets and omics data directly to Source-traceable target evidence table, Disease–target–pathway network, Core modules and validation suggestions. Reporting separates supporting evidence, conflicting signals, parameter dependence and conditions for follow-up validation.
Through which targets and pathways might candidate compounds create synergistic or risk mechanisms?
Suitable research settings
- Projects that need to answer “Through which targets and pathways might candidate compounds create synergistic or risk mechanisms?”
- Studies requiring consistent comparison and quality control across Target prediction and evidence grading and Disease genes, PPI and pathway networks
- Teams that need Source-traceable target evidence table, Disease–target–pathway network, Core modules and validation suggestions with complete reproduction records
Analyses included in the service
Target prediction and evidence grading
Apply Target prediction and evidence grading to compound structures or ingredient list and produce source-traceable target evidence table. First confirm that compound structures or ingredient list can support the downstream analysis.
Disease genes, PPI and pathway networks
Apply Disease genes, PPI and pathway networks to disease, phenotype and tissue context and produce disease–target–pathway network. Use consistent systems, conditions and naming across adjacent steps so comparisons remain reviewable.
Topology, enrichment and mechanism-module analysis
Apply Topology, enrichment and mechanism-module analysis to optional experimental targets and omics data and produce core modules and validation suggestions. Use consistent systems, conditions and naming across adjacent steps so comparisons remain reviewable.
Select the methodological level for the question
| Method | Best suited to | Watch for |
|---|---|---|
| Target prediction and evidence grading | Establishing the input baseline and initial search space for Network pharmacology and target-mechanism analysis | Errors in Network pharmacology and target-mechanism analysis input state, structure or data definition propagate through later steps |
| Disease genes, PPI and pathway networks | Comparing candidate states, features or mechanisms in Network pharmacology and target-mechanism analysis to form priorities | Network pharmacology and target-mechanism analysis comparisons require consistent conditions; raw scores are not experimental measurements |
| Topology, enrichment and mechanism-module analysis | Reviewing key Network pharmacology and target-mechanism analysis results, interpreting differences and recording uncertainty | Database co-occurrence and network topology do not prove direct action or efficacy; central targets require experiments. |
From question definition to reproducible delivery
Frame the research question
Use “Through which targets and pathways might candidate compounds create synergistic or risk mechanisms?” to define comparators, decision use, experimental context and the strength of evidence the computation can support.
Review and curate inputs
Review Compound structures or ingredient list, Disease, phenotype and tissue context, Optional experimental targets and omics data; resolve structure, naming, unit, batch or microstate issues and record any remaining assumptions.
Design methods and controls
Combine Target prediction and evidence grading, Disease genes, PPI and pathway networks, Topology, enrichment and mechanism-module analysis with controls, replicates, sensitivity checks or independent evidence, defining decision criteria before computation.
Compute with quality control
Run Network pharmacology and target-mechanism analysis, including Target prediction and evidence grading, in a reproducible environment; retain inputs, versions, parameters, logs and intermediate outputs, and flag convergence, sampling, data-quality and applicability issues.
Interpret and deliver
Organise Source-traceable target evidence table, Disease–target–pathway network, Core modules and validation suggestions while separating direct observations, model inference and working hypotheses, then prioritise experiments or follow-up computation.
What is needed and what is delivered
Inputs
- Compound structures or ingredient list
- Disease, phenotype and tissue context
- Optional experimental targets and omics data
Optional supporting inputs
- Known positive, negative or reference systems for basic expectation checks in Network pharmacology and target-mechanism analysis
- Replicate experiments, external databases or literature evidence relevant to Network pharmacology and target-mechanism analysis
- Timing, compute, software-compatibility or delivery-format constraints for Network pharmacology and target-mechanism analysis
Deliverables
- Source-traceable target evidence table
- Disease–target–pathway network
- Core modules and validation suggestions
Quality control and interpretation limits
How results are reviewed
- Network pharmacology and target-mechanism analysis: Audit sample metadata, batches, missingness and confounders
- Network pharmacology and target-mechanism analysis: Use strict splits and compare with interpretable simple baselines
- Network pharmacology and target-mechanism analysis: Assess multiple testing, calibration, uncertainty and sensitivity
- Network pharmacology and target-mechanism analysis: Review with independent cohorts, external atlases or orthogonal experiments
Boundaries that remain
- Database co-occurrence and network topology do not prove direct action or efficacy; central targets require experiments.
- Network pharmacology and target-mechanism analysis results apply only to the recorded inputs, parameters, models and sampling scope. Changes to input state, comparison conditions or project objectives may require new computation.
Common ways projects begin
From one system to comparable candidates
When compound structures or ingredient list are available but decision criteria are inconsistent, establish baselines and controls, then use Target prediction and evidence grading, Disease genes, PPI and pathway networks, Topology, enrichment and mechanism-module analysis to build candidate tiers and deliver source-traceable target evidence table with a difference analysis.
Independent review of existing results
When results relevant to Network pharmacology and target-mechanism analysis conflict, revisit compound structures or ingredient list and analytical assumptions around Target prediction and evidence grading, then add replicates, sensitivity checks or alternative models to distinguish signal from method conditions.
Questions before a project begins
What is required before Network pharmacology and target-mechanism analysis begins?
The minimum inputs are Compound structures or ingredient list, Disease, phenotype and tissue context, Optional experimental targets and omics data. If information is incomplete, an input audit identifies which gaps change method selection and which can be handled as explicit assumptions.
Can the result directly prove “Through which targets and pathways might candidate compounds create synergistic or risk mechanisms?”?
No single model output should be treated as experimental fact. Database co-occurrence and network topology do not prove direct action or efficacy; central targets require experiments. Quality controls determine whether results support a priority or mechanism hypothesis; key conclusions still require appropriate experiments or independent data.
Which reusable files are delivered?
Typical delivery includes Source-traceable target evidence table, Disease–target–pathway network, Core modules and validation suggestions, together with input-curation records, key parameters, software and database versions, quality-control results, editable figures and limitations. Exact raw formats are confirmed in the project plan.